


Edecesertib

Cat. No.:	HY-147264
CAS No.:	2408839-73-4
Molecular Formula:	C ₂₂ H ₂₂ FN ₇ O ₂
Molecular Weight:	435.45
Target:	IRAK
Pathway:	Immunology/Inflammation
Storage:	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (229.65 mM; Need ultrasonic)																					
	<table border="1"> <thead> <tr> <th rowspan="2">Solvent</th> <th rowspan="2">Mass</th> <th colspan="3">Concentration</th> </tr> <tr> <th>1 mg</th> <th>5 mg</th> <th>10 mg</th> </tr> </thead> <tbody> <tr> <td rowspan="3">Preparing Stock Solutions</td> <td>1 mM</td> <td>2.2965 mL</td> <td>11.4824 mL</td> <td>22.9647 mL</td> </tr> <tr> <td>5 mM</td> <td>0.4593 mL</td> <td>2.2965 mL</td> <td>4.5929 mL</td> </tr> <tr> <td>10 mM</td> <td>0.2296 mL</td> <td>1.1482 mL</td> <td>2.2965 mL</td> </tr> </tbody> </table>	Solvent	Mass	Concentration			1 mg	5 mg	10 mg	Preparing Stock Solutions	1 mM	2.2965 mL	11.4824 mL	22.9647 mL	5 mM	0.4593 mL	2.2965 mL	4.5929 mL	10 mM	0.2296 mL	1.1482 mL	2.2965 mL
Solvent	Mass			Concentration																		
		1 mg	5 mg	10 mg																		
Preparing Stock Solutions	1 mM	2.2965 mL	11.4824 mL	22.9647 mL																		
	5 mM	0.4593 mL	2.2965 mL	4.5929 mL																		
	10 mM	0.2296 mL	1.1482 mL	2.2965 mL																		
	Please refer to the solubility information to select the appropriate solvent.																					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.74 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.74 mM); Clear solution 																					

BIOLOGICAL ACTIVITY

Description	Edecesertib (GS-5718) is a selective, potent, orally active IRAK-4 inhibitor. Edecesertib has anti-inflammatory activity. Edecesertib can be used for rheumatoid arthritis (RA) and lupus erythematosus (LE) research ^{[1][2]} .
--------------------	---

REFERENCES

- [1]. Roedder S, et, al. Phase 1 Study Results of GS-5718, an Oral IRAK4-Inhibitor: Pharmacodynamics of Single and Multiple Doses of GS-5718 in Healthy Subjects. 2021 Nov 6.
- [2]. WHO Drug Information. International Nonproprietary Names for Pharmaceutical

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA